Aurobindo Pharma expecting first biosimilar approval in US in 12-18 months

03 Dec 2018 Evaluate

Aurobindo Pharma is expecting to receive an approval for its first biosimilar product in the US in the next 12-18 months, while in Europe, the company hopes a green signal by 2022.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1353.50 14.00 (1.05%)
10-Apr-2026 13:44 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1651.60
Dr. Reddys Lab 1227.60
Cipla 1235.00
Zydus Lifesciences 914.80
Lupin 2330.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×